Polyoxometalate exerts broad-spectrum activity against human respiratory viruses hampering viral entry
Antiviral Res. 2024 Apr 27:105897. doi: 10.1016/j.antiviral.2024.105897. Online ahead of print.ABSTRACTHuman respiratory viruses have an enormous impact on national health systems, societies, and economy due to the rapid airborne transmission and epidemic spread of such pathogens, while effective specific antiviral drugs to counteract infections are still lacking. Here, we identified two Keggin-type polyoxometalates (POMs), [TiW11CoO40]8- (TiW11Co) and [Ti2PW10O40]7- (Ti2PW10), endowed with broad-spectrum activity against enveloped and non-enveloped human respiratory viruses, i.e., coronavirus (HCoV-OC43), rhinovirus (HRV-...
Source: Antiviral Research - April 30, 2024 Category: Virology Authors: Irene Arduino Rachele Francese Andrea Civra Elisa Feyles Monica Argenziano Marco Volante Roberta Cavalli Ali M Mougharbel Ulrich Kortz Manuela Donalisio David Lembo Source Type: research
Polyoxometalate exerts broad-spectrum activity against human respiratory viruses hampering viral entry
Antiviral Res. 2024 Apr 27:105897. doi: 10.1016/j.antiviral.2024.105897. Online ahead of print.ABSTRACTHuman respiratory viruses have an enormous impact on national health systems, societies, and economy due to the rapid airborne transmission and epidemic spread of such pathogens, while effective specific antiviral drugs to counteract infections are still lacking. Here, we identified two Keggin-type polyoxometalates (POMs), [TiW11CoO40]8- (TiW11Co) and [Ti2PW10O40]7- (Ti2PW10), endowed with broad-spectrum activity against enveloped and non-enveloped human respiratory viruses, i.e., coronavirus (HCoV-OC43), rhinovirus (HRV-...
Source: Antiviral Research - April 30, 2024 Category: Virology Authors: Irene Arduino Rachele Francese Andrea Civra Elisa Feyles Monica Argenziano Marco Volante Roberta Cavalli Ali M Mougharbel Ulrich Kortz Manuela Donalisio David Lembo Source Type: research
CK1 and PP1 regulate Rift Valley fever virus genome replication through L protein phosphorylation
This study shows that RVFV L protein is serine phosphorylated and identified Casein Kinase 1 alpha (CK1α) and protein phosphatase 1 alpha (PP1α) as L protein binding partners. Inhibition of CK1 and PP1 through small molecule inhibitor treatment, D4476 and 1E7-03, respectively, caused a change in the phosphorylated status of the L protein. Inhibition of PP1α resulted in increased L protein phosphorylation whereas inhibition of CK1α decreased L protein phosphorylation. It was also found that in RVFV infected cells, PP1α localized to the cytoplasmic compartment. Treatment of RVFV infected cells with CK1 inhibitors reduce...
Source: Antiviral Research - April 28, 2024 Category: Virology Authors: Nicole Bracci Alan Baer Rafaela Flor Kaylee Petraccione Timothy Stocker Weidong Zhou Tatiana Ammosova Rhoel R Dinglasan Sergei Nekhai Kylene Kehn-Hall Source Type: research
Current and future use of antibody-based passive immunity to prevent or control HBV/HDV infections
Antiviral Res. 2024 Apr 26:105893. doi: 10.1016/j.antiviral.2024.105893. Online ahead of print.ABSTRACTWith the increasing momentum and success of monoclonal antibody therapy in conventional medical practices, there is a revived emphasis on the development of monoclonal antibodies targeting the hepatitis B surface antigen (anti-HBs) for the treatment of chronic hepatitis B (HBV) and hepatitis D (HDV). Combination therapies of anti-HBs monoclonal antibodies, and novel anti-HBV compounds and immunomodulatory drugs presenting a promising avenue to enhanced therapeutic outcomes in HBV/HDV cure regimens. In this review, we will...
Source: Antiviral Research - April 28, 2024 Category: Virology Authors: Adam J Gehring Loghman Salimzadeh Source Type: research
The lack of HBsAg secretion does neither facilitate induction of antiviral T cell responses nor Hepatitis B Virus clearance in mice
Antiviral Res. 2024 Apr 26:105896. doi: 10.1016/j.antiviral.2024.105896. Online ahead of print.ABSTRACTImmune tolerance to the hepatitis B virus (HBV) is crucial for developing chronic hepatitis, and the HBV surface antigen (HBsAg) produced and secreted in high amounts is regarded as a key contributor. HBsAg is expressed in HBV-infected hepatocytes and those carrying an HBV integration. Whether either HBsAg secretion or the high antigen amount expressed in the liver determines its immunomodulatory properties, however, remains unclear. We, therefore, developed a novel HBV animal model that allowed us to study the role of se...
Source: Antiviral Research - April 28, 2024 Category: Virology Authors: Thomas Michler Jakob Zillinger Philipp Hagen Fuwang Cheng Julia Festag Anna Kosinska Ulrike Protzer Source Type: research
CK1 and PP1 regulate Rift Valley fever virus genome replication through L protein phosphorylation
This study shows that RVFV L protein is serine phosphorylated and identified Casein Kinase 1 alpha (CK1α) and protein phosphatase 1 alpha (PP1α) as L protein binding partners. Inhibition of CK1 and PP1 through small molecule inhibitor treatment, D4476 and 1E7-03, respectively, caused a change in the phosphorylated status of the L protein. Inhibition of PP1α resulted in increased L protein phosphorylation whereas inhibition of CK1α decreased L protein phosphorylation. It was also found that in RVFV infected cells, PP1α localized to the cytoplasmic compartment. Treatment of RVFV infected cells with CK1 inhibitors reduce...
Source: Antiviral Research - April 28, 2024 Category: Virology Authors: Nicole Bracci Alan Baer Rafaela Flor Kaylee Petraccione Timothy Stocker Weidong Zhou Tatiana Ammosova Rhoel R Dinglasan Sergei Nekhai Kylene Kehn-Hall Source Type: research
Current and future use of antibody-based passive immunity to prevent or control HBV/HDV infections
Antiviral Res. 2024 Apr 26:105893. doi: 10.1016/j.antiviral.2024.105893. Online ahead of print.ABSTRACTWith the increasing momentum and success of monoclonal antibody therapy in conventional medical practices, there is a revived emphasis on the development of monoclonal antibodies targeting the hepatitis B surface antigen (anti-HBs) for the treatment of chronic hepatitis B (HBV) and hepatitis D (HDV). Combination therapies of anti-HBs monoclonal antibodies, and novel anti-HBV compounds and immunomodulatory drugs presenting a promising avenue to enhanced therapeutic outcomes in HBV/HDV cure regimens. In this review, we will...
Source: Antiviral Research - April 28, 2024 Category: Virology Authors: Adam J Gehring Loghman Salimzadeh Source Type: research
The lack of HBsAg secretion does neither facilitate induction of antiviral T cell responses nor Hepatitis B Virus clearance in mice
Antiviral Res. 2024 Apr 26:105896. doi: 10.1016/j.antiviral.2024.105896. Online ahead of print.ABSTRACTImmune tolerance to the hepatitis B virus (HBV) is crucial for developing chronic hepatitis, and the HBV surface antigen (HBsAg) produced and secreted in high amounts is regarded as a key contributor. HBsAg is expressed in HBV-infected hepatocytes and those carrying an HBV integration. Whether either HBsAg secretion or the high antigen amount expressed in the liver determines its immunomodulatory properties, however, remains unclear. We, therefore, developed a novel HBV animal model that allowed us to study the role of se...
Source: Antiviral Research - April 28, 2024 Category: Virology Authors: Thomas Michler Jakob Zillinger Philipp Hagen Fuwang Cheng Julia Festag Anna Kosinska Ulrike Protzer Source Type: research
SARS-CoV-2 evolution has increased resistance to monoclonal antibodies and first-generation COVID-19 vaccines: Is there a future therapeutic role for soluble ACE2 receptors for COVID-19?
Antiviral Res. 2024 Apr 25:105894. doi: 10.1016/j.antiviral.2024.105894. Online ahead of print.ABSTRACTCOVID-19 has caused calamitous health, economic and societal consequences. Although several COVID-19 vaccines have received full authorization for use, global deployment has faced political, financial and logistical challenges. The efficacy of first-generation COVID-19 vaccines is waning and breakthrough infections are allowing ongoing transmission and evolution of SARS-CoV-2. Furthermore, COVID-19 vaccine efficacy relies on a functional immune system. Despite receiving three primary doses and three or more heterologous b...
Source: Antiviral Research - April 27, 2024 Category: Virology Authors: Rohan Ameratunga Anthony Jordan Klaus Lehnert Euphemia Leung Emily R Mears Russell Snell Richard Steele See-Tarn Woon Source Type: research
Interim analysis of the PARADISE study: Benefits of add-on peginterferon- α in NA-treated patients with CHB
This study aimed to investigate whether peginterferon-α (IFN) add-on nucleos(t)ide analogs(NAs) can further reduce hepatocellular carcinoma(HCC) risk compared with NAs monotherapy in NA-treated patients with chronic hepatitis B(CHB). In this multi-center randomized controlled trial "PARADISE study" (NCT05671315), CHB patients with intermediate to high risk of HCC after more than 24-week NAs pretreatment were recruited, randomized to two groups at a ratio of 1:2 and followed up for 240 weeks. NAs group maintained NAs monotherapy, while IFN + NAs group received IFN add-on NAs therapy for 48 weeks, then switched to NAs monot...
Source: Antiviral Research - April 25, 2024 Category: Virology Authors: Shaowen Jiang Simin Guo Yan Huang Jie Xu Yi Li Yilan Zeng Yuan Guo Lijuan Ouyang Chuanwu Zhu Weifeng Zhao Qin Zhang Qing Guo Haiguang Xin Qing Xie Source Type: research
Interim analysis of the PARADISE study: benefits of add-on peginterferon- α in NA-treated patients with CHB
This study aimed to investigate whether peginterferon-α (IFN) add-on nucleos(t)ide analogs(NAs) can further reduce hepatocellular carcinoma(HCC) risk compared with NAs monotherapy in NA-treated patients with chronic hepatitis B(CHB). In this multi-center randomized controlled trial "PARADISE study" (NCT05671315), CHB patients with intermediate to high risk of HCC after more than 24-week NAs pretreatment were recruited, randomized to two groups at a ratio of 1:2 and followed up for 240 weeks. NAs group maintained NAs monotherapy, while IFN+NAs group received IFN add-on NAs therapy for 48 weeks, then switched to NAs monothe...
Source: Antiviral Research - April 25, 2024 Category: Virology Authors: Shaowen Jiang Simin Guo Yan Huang Jie Xu Yi Li Yilan Zeng Yuan Guo Lijuan Ouyang Chuanwu Zhu Weifeng Zhao Qin Zhang Qing Guo Haiguang Xin Qing Xie Source Type: research
Interim analysis of the PARADISE study: benefits of add-on peginterferon- α in NA-treated patients with CHB
This study aimed to investigate whether peginterferon-α (IFN) add-on nucleos(t)ide analogs(NAs) can further reduce hepatocellular carcinoma(HCC) risk compared with NAs monotherapy in NA-treated patients with chronic hepatitis B(CHB). In this multi-center randomized controlled trial "PARADISE study" (NCT05671315), CHB patients with intermediate to high risk of HCC after more than 24-week NAs pretreatment were recruited, randomized to two groups at a ratio of 1:2 and followed up for 240 weeks. NAs group maintained NAs monotherapy, while IFN+NAs group received IFN add-on NAs therapy for 48 weeks, then switched to NAs monothe...
Source: Antiviral Research - April 25, 2024 Category: Virology Authors: Shaowen Jiang Simin Guo Yan Huang Jie Xu Yi Li Yilan Zeng Yuan Guo Lijuan Ouyang Chuanwu Zhu Weifeng Zhao Qin Zhang Qing Guo Haiguang Xin Qing Xie Source Type: research
Discovery of baloxavir sodium as a novel anti-CCHFV inhibitor: biological evaluation of in vitro and in vivo
This study identified baloxavir sodium as a novel scaffold structure and mechanism of anti-CCHF compound, providing a promising new strategy for clinical treatment of CCHF after further optimization.PMID:38657838 | DOI:10.1016/j.antiviral.2024.105890 (Source: Antiviral Research)
Source: Antiviral Research - April 24, 2024 Category: Virology Authors: Kai Liu Liushuai Li Yajie Liu Xi Wang Jia Liu Jiang Li Fei Deng Runze Zhang Yiwu Zhou Zhihong Hu Wu Zhong Manli Wang Chun Guo Source Type: research
Inhibition of Pim kinases triggers a broad antiviral activity by affecting innate immunity and via the PI3K-Akt-mTOR axis the endolysosomal system
Antiviral Res. 2024 Apr 20;226:105891. doi: 10.1016/j.antiviral.2024.105891. Online ahead of print.ABSTRACTZoonoses such as ZIKV and SARS-CoV-2 pose a severe risk to global health. There is urgent need for broad antiviral strategies based on host-targets filling gaps between pathogen emergence and availability of therapeutic or preventive strategies. Significant reduction of pathogen titers decreases spread of infections and thereby ensures health systems not being overloaded and public life to continue. Based on previously observed interference with FGFR1/2-signaling dependent impact on interferon stimulated gene (ISG)-ex...
Source: Antiviral Research - April 22, 2024 Category: Virology Authors: Mirco Glitscher Nuka Ivalu Benz Catarina Sabino Robin Oliver Murra Sascha Hein Tobias Zahn Ines Mhedhbi Debora Stefanova Daniela Bender Sabine Werner Eberhard Hildt Source Type: research
Inhibition of Pim kinases triggers a broad antiviral activity by affecting innate immunity and via the PI3K-Akt-mTOR axis the endolysosomal system
Antiviral Res. 2024 Apr 20:105891. doi: 10.1016/j.antiviral.2024.105891. Online ahead of print.ABSTRACTZoonoses such as ZIKV and SARS-CoV-2 pose a severe risk to global health. There is urgent need for broad antiviral strategies based on host-targets filling gaps between pathogen emergence and availability of therapeutic or preventive strategies. Significant reduction of pathogen titers decreases spread of infections and thereby ensures health systems not being overloaded and public life to continue. Based on previously observed interference with FGFR1/2-signaling dependent impact on interferon stimulated genes (ISGs)-expr...
Source: Antiviral Research - April 22, 2024 Category: Virology Authors: Mirco Glitscher Nuka Ivalu Benz Catarina Sabino Robin Murra Sascha Hein Tobias Zahn Ines Mhedhbi Debora Stefanova Daniela Bender Sabine Werner Eberhard Hildt Source Type: research
